Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment

被引：0
|
作者：
Lichtenstein, Gary R. [1 ]
Loftus, Edward V., Jr. [2 ]
Bloom, Stuart [3 ]
Lawendy, Nervin [4 ]
Chan, Gary [4 ]
Friedman, Gary S. [4 ]
Zhang, Haiying [4 ]
Wang, Wenjin [4 ]
Thorpe, Andrew J. [4 ]
Nduaka, Chudy I. [4 ]
Su, Chinyu [4 ]
机构：
[1] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Coll London Hosp NHS Fdn Trust, London, England
[4] Pfizer Inc, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2018年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
571
引用
收藏
页码：S328 / S328
页数：1
相关论文
共 50 条
  • [1] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Soonasra, Arif
    Lawendy, Nervin
    Chan, Gary
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Bloom, Stuart
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S413 - S414
  • [2] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: Open-Label, Long-term Extension Study
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Bloom, Stuart
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S395 - S395
  • [3] TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.9 YEARS OF TREATMENT
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Wei, Shu Chen
    Damiao, Aderson O.
    Judd, Donna
    Lawendy, Nervin
    Chan, Gary
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Bloom, Stuart
    GASTROENTEROLOGY, 2020, 158 (06) : S1190 - S1191
  • [4] Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
    Lichtenstein, G. R.
    Loftus, E. V., Jr.
    Wei, S. C.
    Damiao, A. O.
    Judd, D.
    Lawendy, N.
    Chan, G.
    Zhang, H.
    Wang, W.
    Thorpe, A. J.
    Bloom, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S100 - S101
  • [5] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Bloom, Stuart
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    GUT, 2018, 67 : A62 - A63
  • [6] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Wood, Susan P.
    Terry, Ketti K.
    Nakamura, Hiroyuki
    Ohno, Yukako
    Gruben, David
    Benda, Birgitta
    Wang, Lisy
    Riese, Richard
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993
  • [7] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION UP TO 6 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K. K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Wang, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 259 - 259
  • [8] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years.
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Riese, R.
    Wang, L.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S375 - S375
  • [9] Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment
    Sandborn, William J.
    Lawendy, Nervin
    Danese, Silvio
    Su, Chinyu
    Loftus, Edward V., Jr.
    Hart, Ailsa
    Dotan, Iris
    Damiao, Aderson O. M. C.
    Judd, Donna T.
    Guo, Xiang
    Modesto, Irene
    Wang, Wenjin
    Panes, Julian
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 464 - 478
  • [10] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
    Wollenhaupt, Jurgen
    Silverfield, Joel C.
    Lee, Eun Bong
    Wood, Susan P.
    Soma, Koshika
    Wang, Lisy
    Nakamura, Hiroyuki
    Komuro, Yoshihiro
    Nduaka, Chudi I.
    Gruben, David
    Benda, Birgitta
    Zwillich, Samuel H.
    Riese, Richard
    Bradley, John D.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S548 - S549
12345